MARKET

CFMS

CFMS

Conformis
NASDAQ
0.2070
+0.0158
+8.26%
After Hours: 0.2096 +0.0026 +1.26% 16:02 10/03 EDT
OPEN
0.2000
PREV CLOSE
0.1912
HIGH
0.2140
LOW
0.1903
VOLUME
260.99K
TURNOVER
0
52 WEEK HIGH
1.338
52 WEEK LOW
0.1850
MARKET CAP
38.89M
P/E (TTM)
-0.6132
1D
5D
1M
3M
1Y
5Y
US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Wednesday after recording sharp losses on Tuesday. All the three major indices settled sharply lower, notching their biggest single-session percentage declines since June 2020.
Benzinga · 09/14 09:57
BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Benzinga · 09/14 09:19
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Benzinga · 09/13 22:45
Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System
Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System. Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.
Benzinga · 09/13 20:58
Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip system
Conformis (NASDAQ:CFMS) stock jumped ~17% after hours on Tuesday ...
Seekingalpha · 09/13 20:56
Conformis Actera Hip System Receives 510(k) Clearance From The U.S. FDA
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug
Benzinga · 09/13 20:30
Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration
New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implantsBILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NAS...
GlobeNewswire · 09/13 20:30
ConforMIS Gets FDA Marketing Clearance for Actera Hip System; Shares Surge After Hours
ConforMIS Gets FDA Marketing Clearance for Actera Hip System; Shares Surge After Hours
MT Newswires · 09/13 17:12
More
About CFMS
ConforMIS, Inc. is a medical technology company. The Company is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's unique knee and hip anatomy. The Company’s products include iUni, iDuo, iTotal CR, iTotal PS, iTotal Identity, Identity Imprint and Conformis Cordera hip system. The Company’s iFit Image-to-Implant technology platform includes iFit Design, iFit Printing and iFit Just-in-Time Delivery. Its Identity Imprint knee system provides a data-informed knee implant system that provides a level of personalization through its patient-specific instruments (PSI) and proprietary algorithms for pre-surgical planning. Its Image-to-Implant Platinum Services program offering services in United States. The Company offers a line of the sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.

Webull offers kinds of ConforMIS Inc stock information, including NASDAQ:CFMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFMS stock methods without spending real money on the virtual paper trading platform.